Pfizer and AstraZeneca seek new revenue streams as COVID subsides
Alena Butor/iStock via Getty Images Although the COVID-19 pandemic has ended up being a cash cow for several pharmaceutical and biotech companies, many are looking for other treatments to focus on to replace revenues that are beginning to fade. With their mRNA vaccines, Moderna (NASDAQ:ARNM), Pfizer (NYSE: PFE), and BioNTech (BNTX) have been among the…